Skip to main content
Erschienen in: Supportive Care in Cancer 1/2010

01.01.2010 | Original Article

Oral mucositis in patients receiving reduced-intensity regimens for allogeneic hematopoietic cell transplantation: comparison with conventional regimen

verfasst von: Kanayo Takahashi, Yoshihiko Soga, Yumeno Murayama, Mika Udagawa, Hitomi Nishimoto, Yuko Sugiura, Yoshinobu Maeda, Mitsune Tanimoto, Shogo Takashiba

Erschienen in: Supportive Care in Cancer | Ausgabe 1/2010

Einloggen, um Zugang zu erhalten

Abstract

Goals of work

Severe oral mucositis induced by allogeneic hematopoietic cell transplantation (HCT) is associated with intolerable pain and risk of systemic bacteremia infection. Differences between conventional HCT and reduced-intensity regimens for allogeneic HCT (RIST) may influence the occurrence and severity of oral mucositis. Here, we evaluated oral mucositis in patients undergoing RIST and compared the results with those in conventional allogeneic HCT patients to facilitate predictive measures for mucositis.

Patients and methods

A total of 127 consecutive patients undergoing HCT (conventional, 63; RIST, 64) were included in this study. Severity of oral mucositis during HCT period was evaluated daily. Differences in severity of mucositis among HCT types were analyzed. Use of morphine to control pain due to oral mucositis was evaluated in each HCT method.

Main results

The severity of oral mucositis was reduced in patients undergoing RIST. Worsening of oral mucositis was delayed in patients receiving RIST. Use of morphine to control pain due to oral mucositis was significantly decreased in patients undergoing RIST compared with those receiving conventional allogeneic HCT.

Conclusions

The severity of oral mucositis was reduced and the peak day of oral mucositis was delayed in RIST patients compared with those receiving conventional HCT.
Literatur
1.
Zurück zum Zitat Bellm LA, Epstein JB, Rose-Ped A, Martin P, Fuchs HJ (2000) Patient reports of complications of bone marrow transplantation. Support Care Cancer 8:33–39PubMed Bellm LA, Epstein JB, Rose-Ped A, Martin P, Fuchs HJ (2000) Patient reports of complications of bone marrow transplantation. Support Care Cancer 8:33–39PubMed
4.
Zurück zum Zitat Soga Y, Saito T, Nishimura F, Ishimaru F, Mineshiba J, Mineshiba F, Takaya H, Sato H, Kudo C, Kokeguchi S, Fujii N, Tanimoto M, Takashiba S (2008) Appearance of multidrug-resistant opportunistic bacteria on the gingiva during leukemia treatment. J Periodontol 79:181–186. doi:10.1902/jop. 2008.070205 CrossRefPubMed Soga Y, Saito T, Nishimura F, Ishimaru F, Mineshiba J, Mineshiba F, Takaya H, Sato H, Kudo C, Kokeguchi S, Fujii N, Tanimoto M, Takashiba S (2008) Appearance of multidrug-resistant opportunistic bacteria on the gingiva during leukemia treatment. J Periodontol 79:181–186. doi:10.​1902/​jop.​ 2008.​070205 CrossRefPubMed
6.
Zurück zum Zitat Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J, Hayden V, Eilers J, Epstein JB, LeVeque FG, Miller C, Peterson DE, Schubert MM, Spijkervet FK, Horowitz M (2001) Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 19:2201–2205PubMed Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J, Hayden V, Eilers J, Epstein JB, LeVeque FG, Miller C, Peterson DE, Schubert MM, Spijkervet FK, Horowitz M (2001) Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 19:2201–2205PubMed
7.
Zurück zum Zitat Sugiura Y, Soga Y, Tanimoto I, Kokeguchi S, Nishide S, Kono K, Takahashi K, Fujii N, Ishimaru F, Tanimoto M, Yamabe K, Tsutani S, Nishimura F, Takashiba S (2008) Antimicrobial effects of the saliva substitute, Oralbalance, against microorganisms from oral mucosa in the hematopoietic cell transplantation period. Support Care Cancer 16:421–424. doi:10.1007/s00520-007-0391-z CrossRefPubMed Sugiura Y, Soga Y, Tanimoto I, Kokeguchi S, Nishide S, Kono K, Takahashi K, Fujii N, Ishimaru F, Tanimoto M, Yamabe K, Tsutani S, Nishimura F, Takashiba S (2008) Antimicrobial effects of the saliva substitute, Oralbalance, against microorganisms from oral mucosa in the hematopoietic cell transplantation period. Support Care Cancer 16:421–424. doi:10.​1007/​s00520-007-0391-z CrossRefPubMed
8.
Zurück zum Zitat Tardieu C, Cowen D, Thirion X, Franquin JC (1996) Quantitative scale of oral mucositis associated with autologous bone marrow transplantation. Eur J Cancer 32:381–387 Tardieu C, Cowen D, Thirion X, Franquin JC (1996) Quantitative scale of oral mucositis associated with autologous bone marrow transplantation. Eur J Cancer 32:381–387
Metadaten
Titel
Oral mucositis in patients receiving reduced-intensity regimens for allogeneic hematopoietic cell transplantation: comparison with conventional regimen
verfasst von
Kanayo Takahashi
Yoshihiko Soga
Yumeno Murayama
Mika Udagawa
Hitomi Nishimoto
Yuko Sugiura
Yoshinobu Maeda
Mitsune Tanimoto
Shogo Takashiba
Publikationsdatum
01.01.2010
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 1/2010
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-009-0637-z

Weitere Artikel der Ausgabe 1/2010

Supportive Care in Cancer 1/2010 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.